HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Henry, J C. Articles by Holloway, R. Search for Related Content PubMed PubMed Citation Articles by Henry, J C. Articles by Holloway, R.

Review: lorazepam provides the best control for status epilepticus

Clinical impact ratings GP/FP/Primary care IM/Ambulatory care Internal medicine Emergency medicine Neurology

Key Words: status epilepticus • anticonvulsants • lorazepam

The first 150 words of the full text of this article appear below.

METHODS
Data sources Cochrane Epilepsy Group Specialised Register, Cochrane Central Database of Controlled Trials, Medline, EMBASE/Excerpta Medica, and reference lists.

Study selection and assessment randomised or quasi-randomised controlled trials (RCTs) that compared any anticonvulsant drug with placebo or another anticonvulsant drug in patients with premonitory, early stage, established, or refractory SE. Quality assessment of individual studies included randomisation method, baseline comparability of groups, blinding, and intention to treat analysis.

Outcomes outcomes included development of SE, death, continuation of seizures, continuation of SE requiring use of a different drug or general anaesthesia for control, long term disabling sequelae, and need for ventilatory support.

MAIN RESULTS
11 RCTs (n = 2017) met the selection criteria. Patients had premonitory (5 RCTs), established (1 RCT), refractory (1 RCT), and mixed SE (2 RCTs), and 2 RCTs did not define the status. Superior results were seen with intravenous (IV) lorazepam for cessation of seizures and reducing risk of . . . [Full text of this article]

J Craig Henry, MD, Robert Holloway, MD, MPH

University of Rochester Medical Center, Rochester, New York, USA